Cramer's Morning Take: Eli Lilly 4/17/25
Squawk on the Street
00:00
Intro
This chapter explores Eli Lilly's significant advancements, focusing on a nearly 15% rise in stock value and the growing preference among patients for oral medications over injections. The discussion highlights the implications of these changes for patient acceptance and treatment adherence.
Transcript
Play full episode
